BioSpace

Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings

When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.

By BioSpace

1 min read
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights